In the Phase III SERENA-6 study in HR-positive/HER2-negative metastatic Breast Cancer, switching 157 patients to AstraZeneca's oral SERD camizestrant after ESR1 mutation detection in ctDNA cut the risk of progression or death by 56% and improved median PFS to 16 months vs. 9.2 months for 158 controls — but FDA advisers still voted 6-3 that the data did not show a clinically meaningful benefit. The study, first presented at ASCO last year, tested a biomarker-driven treatment switch before radiographic progression and ran into skepticism over trial design, PFS interpretation and immature overall survival data.

Why It Matters To Oncology

• ODAC's vote signals a high bar for ctDNA-guided treatment switching in metastatic Breast Cancer, even when progression-free survival appears strong.

• Panelists questioned whether ESR1 mutation detection in ctDNA should be treated as a surrogate for progression that justifies changing therapy before standard imaging-based progression.

• The decision could shape how drug developers design biomarker-driven trials, especially when endpoints depart from conventional definitions of PFS.

The Financials

• For AstraZeneca, camizestrant is a closely watched pipeline asset in endocrine-sensitive Breast Cancer and part of a broader strategy to expand use of oral SERDs.

• A negative advisory vote raises regulatory risk for any near-term label expansion tied to the SERENA-6 switching strategy.

• Investor focus now shifts to whether later readouts, including overall survival and PFS2, can strengthen the clinical and commercial case.

What They're Saying

• Mayo Clinic statistician Karla Ballman said the PFS result was hard to interpret because it was measured from a biomarker change rather than a standard clinical benchmark, adding that stronger OS data would have changed her vote.

• Sarah Colonna of Huntsman Cancer Institute warned that adopting the approach would require testing many women, even though only a subset may benefit, and said ctDNA mutation detection should not yet be the gold standard for progression.

• National Cancer Institute's Stanley Lipkowitz said the evidence was not sufficient to support such a fundamental change in practice, while AstraZeneca said it remains confident in the regimen's clinical benefit.

What's Next

• AstraZeneca plans to present final PFS2 data from SERENA-6 as a late-breaking abstract at the ASCO meeting in June.

• Overall survival remains immature, and the timing of a more definitive OS readout is still unclear.

• Developers and clinicians will be watching for FDA guidance on how ctDNA endpoints should be incorporated into future oncology trial designs.